No Data
Adaptimmune Therapeutics Analyst Ratings
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.5
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Adaptimmune Therapeutics Is Maintained at Buy by Guggenheim
Shareholders in Adaptimmune Therapeutics (NASDAQ:ADAP) Have Lost 86%, as Stock Drops 26% This Past Week
No Data
No Data
